<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J. Vet. Med. Sci</journal-id><journal-id journal-id-type="publisher-id">JVMS</journal-id><journal-title-group><journal-title>The Journal of Veterinary Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0916-7250</issn><issn pub-type="epub">1347-7439</issn><publisher><publisher-name>The Japanese Society of Veterinary Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26311787</article-id><article-id pub-id-type="pmc">4751121</article-id><article-id pub-id-type="publisher-id">15-0407</article-id><article-id pub-id-type="doi">10.1292/jvms.15-0407</article-id><article-categories><subj-group subj-group-type="heading"><subject>Bacteriology</subject><subj-group><subject>Full Paper</subject></subj-group></subj-group></article-categories><title-group><article-title>Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot
study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>HARADA</surname><given-names>Kazuki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>SASAKI</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>SHIMIZU</surname><given-names>Takae</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1)</label>Department of Veterinary Internal
Medicine, Tottori University, 4&#x02013;101 Minami, Koyama-Cho, Tottori-Shi, Tottori 680&#x02013;8553,
Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Harada, K.,Department of Veterinary
Internal Medicine, Tottori University, 4&#x02013;101 Minami, Koyama-Cho, Tottori-Shi, Tottori
680&#x02013;8553, Japan. e-mail: <email xlink:href="k-harada@muses.tottori-u.ac.jp">k-harada@muses.tottori-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2016</year></pub-date><volume>78</volume><issue>1</issue><fpage>83</fpage><lpage>89</lpage><history><date date-type="received"><day>06</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9;2016 The Japanese Society of Veterinary Science</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p>The study objective was to determine the effect of oral orbifloxacin (ORB) on
antimicrobial susceptibility and composition of fecal coliforms in cats. Nine cats were
randomized to two groups administered a daily oral dose of 2.5 and 5.0 mg ORB/kg for 7
days and a control group (three cats per group). Coliforms were isolated from stool
samples and were tested for susceptibilities to ORB and 5 other drugs. ORB concentration
in feces was measured using high-performance liquid chromatography (HPLC). The coliforms
were undetectable after 2 days of ORB administration, and their number increased in most
cats after termination of the administration. Furthermore, only isolates of
<italic>Escherichia coli</italic> were detected in all cats before administration, and
those of <italic>Citrobacter freundii</italic> were detected after termination of the
administration. <italic>E. coli</italic> isolates exhibited high ORB susceptibility
[Minimum inhibitory concentration (MIC), &#x02264;0.125 <italic>&#x000b5;</italic>g/m<italic>l</italic>]
or relatively low susceptibility (MIC, 1&#x02212;2 <italic>&#x000b5;</italic>g/m<italic>l</italic>) with a
single <italic>gyrA</italic> mutation. <italic>C. freundii</italic> isolates largely
exhibited intermediate ORB susceptibility (MIC, 4
<italic>&#x000b5;</italic>g/m<italic>l</italic>), in addition to resistance to ampicillin and
cefazolin, and harbored <italic>qnrB</italic>, but not a <italic>gyrA</italic> mutation.
HPLC revealed that the peaks of mean concentration were 61.3 and 141.0
<italic>&#x000b5;</italic>g/g in groups receiving 2.5 and 5.0 mg/kg, respectively. Our findings
suggest that oral ORB may alter the total counts and composition of fecal coliform, but is
unlikely to yield highly fluoroquinolone-resistant mutants of <italic>E. coli</italic> and
<italic>C. freundii</italic> in cats, possibly because of the high drug concentration in
feces.</p></abstract><kwd-group><kwd>antimicrobial resistance</kwd><kwd>fecal coliforms</kwd><kwd>feline</kwd><kwd>orbifloxacin</kwd></kwd-group></article-meta></front><body><p>Orbifloxacin (ORB) is a synthetic antimicrobial agent of the fluoroquinolone (FQ) class and
has a wide range of antibacterial activity and high bioavailability [<xref rid="r14" ref-type="bibr">14</xref>]. In companion animal medicine, ORB is approved for treatment of several
bacterial infections, such as urinary tract infection and skin infection, and has been widely
used in many countries [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r32" ref-type="bibr">32</xref>].</p><p>The development of FQ-resistant bacteria increases the risk of FQ treatment failure in
companion animals. In addition to an effect on animal health, the prevalence of FQ-resistant
bacteria may have important consequences for human public health, if the resistant isolates or
resistance determinants are transmitted to humans from their pets [<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. Understanding the
development of FQ resistance is important not only from a veterinary perspective but also from
a global public health perspective. FQ resistance is mainly acquired by the modification of
target enzymes, i.e. DNA gyrase and topoisomerase IV; however, it may also involve the
acquisition of plasmid-mediated quinolone resistance (PMQR) determinants [<xref rid="r13" ref-type="bibr">13</xref>]. Such acquisition of FQ resistance is closely
associated with selective pressure resulting from the use of FQ drugs [<xref rid="r25" ref-type="bibr">25</xref>].</p><p>Coliforms, including <italic>Escherichia coli</italic>, are representative commensal bacteria
in the gut of animals and can act as an indicator of antimicrobial resistance [<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r30" ref-type="bibr">30</xref>]. Notably,
most FQ drugs after administration migrate to the gut and urine [<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r24" ref-type="bibr">24</xref>]; therefore, the gut flora,
including coliforms, is likely exposed to FQs in animals administered with the drugs. To
assess the effect of FQ use on the fecal or gut flora, experiments with FQ administration have
been previously conducted on various animals, such as pigs [<xref rid="r4" ref-type="bibr">4</xref>], chickens [<xref rid="r22" ref-type="bibr">22</xref>] and dogs [<xref rid="r29" ref-type="bibr">29</xref>]. However, the similar experiments have not yet been
performed on cats, a representative species of companion animals.</p><p>In this study, we assessed antimicrobial susceptibility, bacterial species and the number of
fecal coliforms in cats treated with two specific doses of ORB, as well as untreated cats. We
also determined several genetic mechanisms of FQ resistance in coliform bacteria isolated from
treated and untreated cats.</p><sec sec-type="materials|methods" id="s1"><title>MATERIALS AND METHODS</title><p><italic>Study design and enrolled cats</italic>: Nine domestic short-haired cats living at
a research facility were enrolled; mean age was 6.11 &#x000b1; 1.71 years, and body weight was 3.51
&#x000b1; 0.42 kg. All cats were selected from a research colony maintained under standard
laboratory conditions at the Tottori University. None of the cats had received
antimicrobials for at least six months prior to the study, and all cats were deemed healthy
based on a physical examination and a hematological examination. The cats were randomized
into three groups (groups A, B and C) of three cats each. The cats in groups A and B
received a daily oral dose of 5 and 2.5 mg ORB/kg (DS Pharma Animal Health, Osaka, Japan),
respectively, for 7 consecutive days, as approved dosages in Japan. The cats in group C
served as a control. Further, the cats were fed commercial dry cat food and received no
medication other than ORB during the study. All cats were housed in separate cages located
in one room, and direct contact among the cats was prevented during the study. Only when
administered with ORB, the cats were separately led out of each cage. Authors contacting
with the cats wore a new disposable glove in each case. This study was approved by Tottori
University Animal Use Committee (approval number, 13-T-29).</p><p><italic>Isolation and identification of fecal coliforms</italic>: Stool samples were
collected from each of the 9 cats on days 1, 3, 5, 7, 9, 11, 13, 15 and 17. On day 1, the
sample was obtained before drug administration. Serial 10-fold dilutions were then prepared
from 1 g of each stool sample in 0.1% peptone water. Once the appropriate dilution was
prepared, 0.1 m<italic>l</italic> was plated onto eosin methylene blue (EMB) agar (Nissui
Pharmaceutical Co., Ltd., Tokyo, Japan) containing either no drugs or ORB at the
concentration of 2 <italic>&#x000b5;</italic>g/m<italic>l</italic>, which was defined as the
concentration of intermediate susceptibility in to the Clinical and Laboratory Standards
Institute Guidelines [<xref rid="r8" ref-type="bibr">8</xref>]. On EMB agar, coliform
colonies develop a metallic luster, other gram-negative bacteria appear colorless, and
gram-positive bacteria cannot grow. The inoculated plates were incubated at 35&#x000b0;C for 24 hr,
and the number of coliform bacteria was enumerated as colony-forming units (CFU)/g of feces.
A maximum of 10 coliform colonies per cat per sampling were picked up and subjected to
identification of bacterial species. Isolates were confirmed to be <italic>E. coli</italic>
by gram staining, the typical colony shape on deoxycholate hydrogen sulphide lactose agar
(Nissui Pharmaceutical Co., Ltd.) and detection of the <italic>uid</italic> gene by PCR
[<xref rid="r3" ref-type="bibr">3</xref>]. When isolates were not identified as <italic>E.
coli</italic>, they were identified using the API 20E Kit (SYSMEX bioM&#x000e9;rieux Co., Ltd.,
Tokyo, Japan). After bacterial identification, the isolates were stored in 10% skim milk at
&#x02212;80&#x000b0;C for antimicrobial susceptibility testing and genetic analysis. The remaining stool
samples were frozen at &#x02212;80&#x000b0;C until high performance liquid chromatography (HPLC)
analysis.</p><p><italic>Antimicrobial susceptibility testing</italic>: Susceptibility testing against ORB
was conducted using the agar dilution method, according to the Clinical and Laboratory
Standards Institute Guidelines [<xref rid="r9" ref-type="bibr">9</xref>]. In addition,
susceptibilities to ampicillin (AMP), cefazolin (CEZ), tetracycline (TET), chloramphenicol
(CHL), kanamycin (KAN) and trimethoprim/sulfamethoxazole (SXT) were determined using the
disk diffusion method [<xref rid="r9" ref-type="bibr">9</xref>]. The results were
interpreted as per criteria of the CLSI guidelines [<xref rid="r8" ref-type="bibr">8</xref>]. <italic>E. coli</italic> ATCC 25922 was used as the quality control strain. In
CEZ-resistant isolates, AmpC &#x003b2;-lactamase and extended-spectrum &#x003b2;-lactamase (ESBL) were
phenotypically screened using cefoxitin disks (30 <italic>&#x000b5;</italic>g/disk) and cefotaxime
(3 <italic>&#x000b5;</italic>g), respectively; the results were considered positive, if the
inhibition zone diameters were &#x02264;14 and &#x02264;27 mm, respectively [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r28" ref-type="bibr">28</xref>]. Further, AmpC-positive isolates
were defined as derepressed AmpC mutants or inducible AmpC producers, as previously
described [<xref rid="r18" ref-type="bibr">18</xref>].</p><p><italic>Analysis of the mechanism of FQ resistance</italic>: Isolates with an ORB MIC of &#x02265;1
<italic>&#x000b5;</italic>g/m<italic>l</italic> were assessed for the presence of mutations of the
quinolone resistance-determining region (QRDR) and PMQR determinants.</p><p>The QRDR of the <italic>gyrA</italic> gene was amplified by PCR with previously described
primers [<xref rid="r12" ref-type="bibr">12</xref>]. The resulting amplicons were
bidirectionally sequenced using the same primers. The QRDR of the <italic>parC</italic> gene
was also amplified and sequenced using previously described primers [<xref rid="r12" ref-type="bibr">12</xref>], when QRDR mutations were detected in <italic>gyrA</italic>.</p><p>PMQR genes were detected using multiplex PCR as previously reported [<xref rid="r7" ref-type="bibr">7</xref>]. Any ambiguous PCR results were clarified with repeat assays. PCR
products were then randomly selected and bidirectionally sequenced with the same primers for
confirmation.</p><p><italic>Enterobacterial repetitive intergenic consensus sequence-based PCR</italic>:
Enterobacterial repetitive intergenic consensus sequence-based PCR (ERIC-PCR) was carried
out to investigate epidemiologic relationship among the PMQR-positive isolates. The
procedure was slightly modified from the previous studies [<xref rid="r27" ref-type="bibr">27</xref>, <xref rid="r31" ref-type="bibr">31</xref>]. Briefly, the PCR reaction was set
up in a 20 <italic>&#x000b5;l</italic> reaction volume containing 2 <italic>&#x000b5;l</italic> of a 10 &#x000d7;
ExTaq buffer, 1 U of ExTaq DNA polymerase (Takara Bio Inc., Otsu, Japan), 0.25 mM each of
the dNTPs, 10&#x02013;30 <italic>n</italic>g of bacterial DNA and 20 pmol of each primer (i.e.
ERIC1R and ERIC2). DNA amplifications were performed with an initial denaturation (7 min at
94&#x000b0;C) followed by 30 cycles of denaturation (1 min at 94&#x000b0;C), annealing (1min at 52&#x000b0;C) and
extension (8 min at 65&#x000b0;C) with a final extension (15 min at 65&#x000b0;C).</p><p><italic>Measurement of ORB concentration in feces</italic>: Stool samples were obtained
from cats in groups A and B on days 1, 3, 5, 7 and 9 and from cats in group C on days 1 and
9. The concentration of ORB in feces was determined at the Research Institute for Animal
Science in Biochemistry and Toxicology (Sagamihara, Japan). In brief, ORB in stool samples
was extracted with acetonitrile containing 1% formic acid and purified via liquid&#x02013;liquid
partition, salting-out and a mini-column (Oasis MAX<sup>&#x000ae;</sup>, Nihon Waters K.K., Tokyo,
Japan). ORB was analyzed using an HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped
with a binary pump, an autosampler, a column heater and a fluorescence detector. For
separation, Supelcosil Abzplus (Sigma&#x02013;Aldrich Co., LLC, Tokyo, Japan) was concurrently used
with LiChroCART 4-4 LiChrosher 100 RP-18 Guard Column (Merck, Tokyo, Japan). Limitation of
quantitation was determined as 0.1 <italic>&#x000b5;</italic>g/g. The quality control was carried
out by analyzing stool samples together with samples of known concentrations (i.e. 0.2 and 2
<italic>&#x000b5;</italic>g/g) every time.</p><p><italic>Statistical analysis</italic>: Standard one-way analysis of variance with the
Tukey&#x02013;Kramer multiple comparison test was used to compare the mean age and body weight of
the enrolled cats, and mean CFU/g of stool samples among groups A, B and C. The Mann&#x02013;Whitney
<italic>U</italic> test was used to compare mean concentrations of ORB in feces between
groups A and B. Fisher&#x02019;s exact test was used to compare rates of antimicrobial resistance
between groups and periods (i.e. before and after treatment). A <italic>P</italic> value of
&#x0003c;0.05 was considered as statistically significant in all analyses.</p></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p><italic>Enrolled cats</italic>: There were no differences in age or body weight among the
three groups (<italic>P</italic>&#x0003e;0.05). No adverse effects of the drug were noted in any
cat.</p><p><italic>Total number of coliforms in cats</italic>: The total number of coliforms during
the test schedule is shown in <xref ref-type="fig" rid="fig_001">Fig. 1</xref><fig orientation="portrait" fig-type="figure" id="fig_001" position="float"><label>Fig. 1.</label><caption><p>The means of the total number of coliforms and ORB concentration in the feces of cats
in groups A, B and C during the test schedule. In groups A and B, ORB was administered
orally daily at a dose of 5.0 and 2.5 mg/kg, respectively, on days 1&#x02212;7
(<sup>&#x02194;</sup>). See <xref ref-type="supplementary-material" rid="pdf_001">Supplemental Figs. 1 and 2</xref> for the total number of coliforms and
ORB concentration, respectively, in each cat. <sup>&#x02020;,&#x02021;</sup>Significantly lower number
of coliforms in groups A and B, respectively, compared with group C
(<italic>P</italic>&#x0003c;0.05). *There were significant differences between groups A
and B (<italic>P</italic>&#x0003c;0.05).</p></caption><graphic xlink:href="jvms-78-083-g001"/></fig> and Supplemental Fig. 1. According to the one-way analysis of variance and the
Tukey&#x02013;Kramer multiple comparison test, pre-treatment coliform counts in groups A, B and C
were not significantly different (7.08 &#x000b1; 0.53, 5.39 &#x000b1; 0.72 and 6.55 &#x000b1; 1.11,
respectively).</p><p>In groups A and B, within 3 days of ORB administration, the number of fecal coliforms
decreased rapidly and continued to be significantly lower than that of group C
(<italic>P</italic>&#x0003c;0.05), until day 9 or 7, respectively. After cessation of ORB
treatment, coliform counts in the cats of groups A and B mostly reached detectable levels by
days 9 (cat 3) and 11 (cats 1 and 2) and by days 7 (cat 5) and 9 (cat 6), respectively.
There were no significant differences in coliform counts between groups A and C from day 11
(<italic>P</italic>&#x0003e;0.05). On the other hand, significant differences were found in
coliform counts between groups B and C (<italic>P</italic>&#x0003c;0.05) on days 13, 15 and 17,
because of extremely low counts of coliform in cats 4 and 6. Significant differences between
groups A and B were not seen during the study period (<italic>P</italic>&#x0003e;0.05). No
remarkable fluctuations were observed in coliform counts in the cats of group C during the
study period.</p><p><italic>Rates of antimicrobial resistance of coliforms in cats</italic>: By antimicrobial
susceptibility testing, ORB resistance was not detected in groups A and B before the
treatment. After the treatment, ORB resistance was found in group B (6.0%); however, there
was no significant difference in the resistance rates before and after the treatment
(<italic>P</italic>&#x0003e;0.05). On the other hand, ORB resistance was not detected in group
A after the treatment.</p><p>Compared to before treatment, rates of AMP resistance were significantly high in groups A
and B after the treatment (0% vs. 26.2% and 0% vs. 76.2%, respectively,
<italic>P</italic>&#x0003c;0.01); rates of CEZ resistance were also significantly high in these
groups after the treatment (0% vs. 26.2% and 0% vs. 76.2%, respectively,
<italic>P</italic>&#x0003c;0.01). There were significant differences in rates of resistance to
the two drugs between groups A and B after the treatment (<italic>P</italic>&#x0003c;0.01).</p><p>In group C, resistance to any antimicrobials tested was not detected during test
period.</p><p><italic>Changes in the composition of the bacterial population of fecal coliforms</italic>:
Coliform species are shown in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Bacterial species of coliforms from stool samples obtained from cats during the
test schedule</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" colspan="1">Group<sup>a)</sup></th><th rowspan="3" align="center" valign="middle" colspan="1">Cat</th><th colspan="9" align="center" rowspan="1">Date of sampling (No. of isolates) <sup>b)</sup></th></tr><tr><th colspan="9" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">1</th><th valign="middle" align="center" rowspan="1" colspan="1">3</th><th valign="middle" align="center" rowspan="1" colspan="1">5</th><th valign="middle" align="center" rowspan="1" colspan="1">7</th><th valign="middle" align="center" rowspan="1" colspan="1">9</th><th valign="middle" align="center" rowspan="1" colspan="1">11</th><th valign="middle" align="center" rowspan="1" colspan="1">13</th><th valign="middle" align="center" rowspan="1" colspan="1">15</th><th align="center" rowspan="1" colspan="1">17</th></tr></thead><tbody><tr><td align="center" rowspan="3" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec/Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec<sup>c)</sup>/Cf<sup>c)</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Ec/Cf</td></tr><tr><td colspan="11" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf<sup>c)</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec/Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Cf</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02015;</td></tr><tr><td colspan="11" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td><td align="center" valign="middle" rowspan="1" colspan="1">Ec</td></tr></tbody></table><table-wrap-foot><p>a) Groups A and B were treated with 5 and 2.5 mg ORB/kg, respectively. Group C was
control (untreated). b) ORB was administered orally during days 1&#x02013;7. Ec:
<italic>Escherichia</italic><italic>coli;</italic> Cf: <italic>Citrobacter
freundii</italic>. c) The isolates were also detected using EMB agar containing ORB
(2 <italic>&#x000b5;</italic>g/m<italic>l</italic>) and exhibited low (MIC: 1
<italic>&#x000b5;</italic>g/m<italic>l</italic>) or intermediate susceptibility to ORB (MIC:
2&#x02013;4 <italic>&#x000b5;</italic>g/m<italic>l</italic>).</p></table-wrap-foot></table-wrap>. On day 1, all isolates from cats in groups A, B and C were identified as
<italic>E. coli</italic>.</p><p>After ORB treatment, the isolates of <italic>Citrobacter freundii</italic> were detected in
all cats in groups A and B. In group A, <italic>C. freundii</italic> isolates were detected
on days 11, 13, 15 and/or 17, whereas in group B, the bacteria were detected on days 7, 9,
11, 13 and/or 17. Furthermore, <italic>E. coli</italic> isolates were detected alone or
along with <italic>C. freundii</italic> isolates in all cats except cat 4 (from group B), in
whom coliforms were not detected until day 15 after treatment initiation, and only
<italic>C. freundii</italic> isolates were detected on day 17. In group C, all isolates
were identified as <italic>E. coli</italic>.</p><p>Using EMB agar containing ORB, coliforms were detected with 10<sup>3.08</sup> CFU/g in cat
3 (from group A) on day 15 and with 10<sup>3.28</sup> CFU/g in cat 4 (from group B) on day
17 after treatment initiation; these isolates were identified as <italic>E. coli</italic>
and <italic>C. freundii</italic> (cat 3) and <italic>C. freundii</italic> alone (cat 4). No
growth of coliforms was detected in the other cats by using ORB-containing EMB agar.</p><p>Coliform bacteria other than <italic>E. coli</italic> or <italic>C. freundii</italic> were
not identified during the test schedule.</p><p><italic>Resistance mechanisms in E. coli and C. freundii</italic>: As for ORB resistance,
<italic>E. coli</italic> isolates were highly susceptible (MIC, 0.031&#x02013;0.25
<italic>&#x000b5;</italic>g/m<italic>l</italic>) in cats 1 and 2 (from group A), and 4, 5 and 6
(from group B) not only before treatment but also after treatment (<xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Antimicrobial susceptibility and FQ resistance mechanisms of coliforms from cats
before and after ORB administration</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" colspan="1">Group<sup>a)</sup></th><th rowspan="3" align="center" valign="middle" colspan="1">Cat</th><th rowspan="3" align="center" valign="middle" colspan="1">Period</th><th colspan="2" align="center" valign="middle" rowspan="1">Isolates</th><th rowspan="3" align="center" valign="middle" colspan="1">MIC range of
orbifloxacin(<italic>&#x000b5;</italic>g/m<italic>l</italic>)</th><th colspan="2" align="center" valign="middle" rowspan="1">QRDR mutation</th><th rowspan="3" align="center" valign="middle" colspan="1">PMQR</th><th rowspan="3" align="center" valign="middle" colspan="1">Susceptibility to other antimicrobials</th></tr><tr><th colspan="2" rowspan="1"><hr/></th><th colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Species<sup>b)</sup></th><th align="center" rowspan="1" colspan="1"><italic>n</italic></th><th align="center" rowspan="1" colspan="1">GyrA</th><th align="center" rowspan="1" colspan="1">ParC</th></tr></thead><tbody><tr><td align="center" rowspan="24" colspan="1">A</td><td align="center" rowspan="5" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">Post-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="5" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">Post-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">0.031&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="11" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="9" colspan="1">Post-treatment</td><td align="center" rowspan="3" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0.031&#x02013;0.063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="6" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">S83L<sup>d)</sup></td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Ec<sup>c)</sup></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" rowspan="1" colspan="1">S83L<sup>d)</sup></td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf<sup>c)</sup></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="10" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="19" colspan="1">B</td><td align="center" rowspan="5" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">Post-treatment</td><td align="center" rowspan="1" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf<sup>c)</sup></td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="5" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">Post-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.25</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="7" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Pre-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="5" colspan="1">Post-treatment</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="7" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="3" colspan="1">Cf</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="6" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">None</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>qnrB</italic></td><td align="center" rowspan="1" colspan="1">AMP CEZ</td></tr><tr><td colspan="10" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="5" colspan="1">C</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr><tr><td colspan="9" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">Ec</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.063&#x02013;0.125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Susceptible</td></tr></tbody></table><table-wrap-foot><p>a) Groups A and B were treated with 5 and 2.5 mg ORB/kg, respectively. Group C was
control (untreated). b) Ec: <italic>Escherichia coli</italic>, Cf: <italic>Citrobacter
freundii</italic>. c) The isolates were detected using EMB agar containing ORB (2
<italic>&#x000b5;</italic>g/m<italic>l</italic>). d) S83L: codon position 83,
serine-to-leucine mutation.</p></table-wrap-foot></table-wrap>). On the other hand, isolates with low or intermediate susceptibility (MIC,
1&#x02013;2 <italic>&#x000b5;</italic>g/m<italic>l</italic>) were predominantly detected in cat 3 (from
group 1) after treatment, and these isolates had a single QRDR mutation in
<italic>gyrA</italic> at codon position 83 (serine to leucine: S83L). In group C, all
<italic>E. coli</italic> isolates were highly susceptible to ORB (MIC, 0.063&#x02013;0.125
<italic>&#x000b5;</italic>g/m<italic>l</italic>) during the test schedule. All <italic>C.
freundii</italic> isolates from cats 1&#x02013;5 demonstrated intermediate susceptibility (MIC, 4
<italic>&#x000b5;</italic>g/m<italic>l</italic>), whereas the resistant isolates (MIC, 8
<italic>&#x000b5;</italic>g/m<italic>l</italic>) were barely detectable only in cat 6 on days 9,
11 and 13. According to PCR and sequencing results, none of the <italic>C. freundii</italic>
isolates had QRDR mutations in <italic>gyrA</italic>, but carried <italic>qnrB</italic>, one
of the PMQR genes.</p><p>All <italic>E. coli</italic> isolates were susceptible to the 5 tested antimicrobials,
whereas all <italic>C. freundii</italic> isolates were resistant to AMP and CEZ. All
<italic>C. freundii</italic> isolates were phenotypically confirmed to be inducible AmpC
producers, but not ESBL producers.</p><p><italic>Genetic relationship between C. freundii isolates from cats</italic>: Four
<italic>C. freundii</italic> isolates each from cats 1&#x02013;6 (from groups A and B) were
selected and subjected to ERIC-PCR. As the result, all of these isolates had the identical
banding pattern (data not shown).</p><p><italic>ORB concentration in feces of ORB-treated cats</italic>: The changes in ORB
concentration in feces are shown in <xref ref-type="fig" rid="fig_001">Fig. 1</xref> and
<xref ref-type="supplementary-material" rid="pdf_001">Supplemental Fig. 2</xref>. On day 1 before treatment initiation, ORB was not detected in stool
samples from any cat. ORB was detected in cats of groups A and B between days 3 and 9 after
treatment initiation. Highest concentration of ORB was determined in cats 2 and 6 of groups
A and B, respectively, between days 3 and 7. The peaks of mean concentration in groups A and
B were observed on day 3 (141.0 and 61.3 <italic>&#x000b5;</italic>g/g, respectively). On days 5 and
7, significantly higher concentrations of ORB were detected in group A than in group B
(<italic>P</italic>&#x0003c;0.05). On the other hand, ORB was not detected in all of cats in
group C on days 1 and 9.</p></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>To the best of our knowledge, this is the first study to evaluate the effects of oral FQ on
the fecal flora of cats. We have demonstrated that the counts of coliform bacteria
significantly decreased during and after the period for administration of ORB. A similar
reduction in the number of coliforms was reported in dogs treated with enrofloxacin [<xref rid="r29" ref-type="bibr">29</xref>]. Thus, these data indicate that FQ administration
reduces the number of coliforms in the fecal flora of cats and dogs. As for the composition
of the bacterial population of the fecal coliform bacteria, only <italic>E. coli</italic>
was detected in all cats on day 1, whereas isolates of <italic>C. freundii</italic> and
<italic>E. coli</italic> were detected as a dominant species of all cats in groups A and B
after cessation of ORB treatment. Few reports have addressed the effect of antimicrobial
treatment on the composition of the bacterial population of fecal or gut flora in animals.
Johnson <italic>et al.</italic> [<xref rid="r17" ref-type="bibr">17</xref>] detected the
emergence of <italic>Streptococcus</italic> spp. and <italic>Corynebacterium</italic> spp.
in cats after the administration of metronidazole. Lawrence <italic>et al.</italic> [<xref rid="r19" ref-type="bibr">19</xref>] confirmed the increase in the number of enterococcal
cells in dogs after the administration of cefovecin. Although there were several differences
in test condition between studies, our and their results suggest that administration of
antimicrobials can cause increase, in addition to decrease, of specific bacterial species of
fecal or gut flora, which may be explained by microbial substitution.</p><p>Pharmacokinetics of ORB has not yet been evaluated in animals treated with different doses
of this antibiotic. In this study, we found clear differences in ORB concentrations in feces
between the two doses (5.0 and 2.5 mg/kg). This dose-dependent kinetics of ORB should be
considered when administering this drug. Moreover, our results reveal remarkably high
concentrations of ORB in feces of cats receiving either the high-dose or low-dose treatment.
Thus, ORB is likely to be mostly excreted into the feces after oral administration: a notion
supported by a previous study [<xref rid="r21" ref-type="bibr">21</xref>], revealing that a
higher concentration of ORB is present in bile acid than in serum of cats after ORB
treatment. These pharmacokinetic properties of the drug may be responsible for the
significant reduction of fecal coliforms in cats after treatment.</p><p>Our study showed some variations in the numbers of coliforms and ORB concentrations in
feces between cats administered with the drug, suggesting that effect of ORB treatment on
fecal coliforms and pharmacokinetics of the drug may vary by individual. Such
interindividual variations should be taken into account when administering the drug for
cats.</p><p>Susceptibility testing revealed that no ORB-resistant <italic>E. coli</italic> appeared
because all isolates failed to develop more than one QRDR mutation: the necessary condition
for the acquisition of FQ resistance [<xref rid="r12" ref-type="bibr">12</xref>]. Our
results strongly contradict the study by Aly <italic>et al.</italic> [<xref rid="r2" ref-type="bibr">2</xref>], wherein all fecal <italic>E. coli</italic> isolates exhibit high-level
resistance to enrofloxacin after treatment of dogs with the drug. In general, the concept of
a mutant selection window has considerable implications for the acquisition of FQ
resistance, and antimicrobials at concentrations beyond the mutant prevention concentration
(MPC) can prevent the development of FQ-resistant mutants [<xref rid="r5" ref-type="bibr">5</xref>]. In our study, the fecal ORB concentration in cats treated with the doses of
2.5 and 5.0 mg/kg far exceeds the MPC value of <italic>E. coli</italic> (0.5&#x02013;32
<italic>&#x000b5;</italic>g/m<italic>l</italic>); this result has been confirmed by another study
[<xref rid="r26" ref-type="bibr">26</xref>]. These findings suggest that oral ORB poses a
low risk of selection of highly FQ-resistant mutants among fecal <italic>E. coli</italic>
isolates in cats because of high gut levels.</p><p>Compared with <italic>E. coli</italic> isolates, <italic>C. freundii</italic> isolates show
higher ORB MIC values. Such low susceptibilities to FQs may give a competitive advantage to
<italic>C. freundii</italic> when administered with ORB. Most strains of <italic>C.
freundii</italic> maintained intermediate sensitivity to ORB. Among the tested PMQR genes,
<italic>qnrB</italic> was detected in all <italic>C. freundii</italic> isolates. This
finding can be explained by a study by Jacoby <italic>et al.</italic> [<xref rid="r16" ref-type="bibr">16</xref>], revealing that chromosomal <italic>qnrB</italic> is prevalent in
<italic>C. freundii</italic> isolates. On the other hand, no QRDR mutations of
<italic>gyrA</italic>, the basis of the FQ resistance mechanism [<xref rid="r23" ref-type="bibr">23</xref>], were identified in <italic>C. freundii</italic> isolates. Cesaro
<italic>et al.</italic> [<xref rid="r6" ref-type="bibr">6</xref>] reported that QRDR
mutations can be more effectively suppressed in <italic>qnr</italic>-positive <italic>E.
coil</italic> strains than in <italic>qnr</italic>-negative <italic>E. coli</italic>
strains; this property of <italic>qnr</italic> may elucidate our present results, namely
that <italic>qnrB</italic>-positive <italic>C. freundii</italic> isolates fail to acquire
strong ORB resistance. It should be considered that gut flora of cats can act as a reservoir
of <italic>qnr</italic>-positive bacteria, which are possibly selected as a result of FQ
use. In coliform-positive samples after ORB treatment, <italic>qnr</italic>-positive
<italic>C. freundii</italic> isolates were detected more frequently in group B (8 of 11
samples) than in group A (5 of 13 samples). This finding implies that low-dose treatment of
ORB might facilitate the selection of <italic>qnr</italic>-positive bacteria, compared with
high-dose treatment. However, to clarify this point, further large-scale studies would be
needed.</p><p>As for susceptibilities to the antimicrobials other than FQs, all <italic>E. coli</italic>
isolates exhibited susceptibility to all the tested antimicrobials both before and after ORB
treatment. As a result, multidrug-resistant <italic>E. coli</italic> isolates, which were
reported in dogs after enrofloxacin treatment [<xref rid="r2" ref-type="bibr">2</xref>],
were not detected in the present study. On the other hand, all <italic>C. freundii</italic>
isolates exhibited resistance to AMP and CEZ by the production of AmpC, but not ESBLs. This
finding resulted in the significant increase of resistance rates to AMP and CEZ in isolates
of <italic>E. coli</italic> and <italic>C. freundii</italic> after ORB treatment. Similarly,
the high prevalence of ampC in this bacterial species was previously found in human isolates
in a study by Kanamori <italic>et al.</italic> [<xref rid="r18" ref-type="bibr">18</xref>].
Our study suggests that FQ use poses a risk of coselection of AmpC-producing <italic>C.
freundii</italic> isolates in feces of cats.</p><p>ERIC-PCR revealed that <italic>C. freundii</italic> isolates, which were
<italic>qnrB</italic>-positive and AmpC-producing, from cats 1&#x02013;6 (from groups A and B)
were clonal or genetically identical. This result indicates that <italic>C.
freundii</italic> isolates spread clonally in the cats; however, the cause of the clonal
spread could not be identified. One hypothesis is cross-contamination between the cats
during the study, despite deliberate efforts to prevent this. A similar phenomenon was
reported previously [<xref rid="r19" ref-type="bibr">19</xref>]. Another is that ORB
treatment might select <italic>C. freundii</italic> isolates that had spread horizontally
among enrolled cats before the study. In either case, more aggressive and effective measures
to prevent any transfer of bacteria would be needed for future studies.</p><p>There were several study limitations. Firstly, this study was carried out as a pilot study
by using a small number of cats, and thus, the present results might be somewhat biased.
Secondly, the effect of ORB treatment remains to be clarified in cats with clinical signs or
household cats, because we used healthy experimental cats in research settings. Furthermore,
this study covered only coliform bacteria. Fecal or gut flora in cats is composed of a
variety of aerobic and anaerobic bacteria [<xref rid="r17" ref-type="bibr">17</xref>], in
addition to coliform bacteria. Therefore, this study could not entirely clarify an effect of
ORB treatment on fecal flora of cats.</p><p>Nevertheless, we have described the effects of ORB administration on fecal coliforms in
healthy cats. We revealed alterations in bacterial composition, e.g. selection of
<italic>qnrB</italic>- and AmpC-positive <italic>C. freundii</italic> isolates, in
addition to a decrease in the total number of coliforms. Moreover, we could not detect
strongly FQ-resistant mutants among isolates of <italic>E. coli</italic> and <italic>C.
freundii</italic>. Further studies using household cats with and without clinical signs
are required to assess clinical and public health implications of the effects of FQ use on
the fecal flora of cats.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="pdf_001"><caption><title>Supplement figure</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="jvms-78-083-s001.pdf" orientation="portrait" xlink:type="simple" id="d36e1652" position="anchor"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank Ms. Emiko Shimoda for her technical
assistance. This study was supported by a grant from DS Pharma Animal Health Co., Ltd.,
Japan. The sponsor of the study had no role in the study design, conduct of the study, data
collection, data interpretation or preparation of the manuscript.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Albarellos</surname><given-names>G. A.</given-names></name><name><surname>Landoni</surname><given-names>M. F.</given-names></name></person-group><year>2009</year>. <article-title>Current concepts on the use of
antimicrobials in cats</article-title>. <source><italic>Vet.
J.</italic></source><volume>180</volume>: <fpage>304</fpage>&#x02013;<lpage>316</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tvjl.2008.01.001</pub-id><pub-id pub-id-type="pmid">18314361</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Aly</surname><given-names>S. A.</given-names></name><name><surname>Debavalya</surname><given-names>N.</given-names></name><name><surname>Suh</surname><given-names>S. J.</given-names></name><name><surname>Oryazabal</surname><given-names>O. A.</given-names></name><name><surname>Boothe</surname><given-names>D. M.</given-names></name></person-group><year>2012</year>. <article-title>Molecular mechanism of antimicrobial
resistance in fecal <italic>Escherichia coli</italic> of healthy dogs after enrofloxacin
or amoxicillin administration</article-title>. <source><italic>Can. J.
Microbiol.</italic></source><volume>58</volume>:
<fpage>1288</fpage>&#x02013;<lpage>1294</lpage>. doi: <pub-id pub-id-type="doi">10.1139/w2012-105</pub-id><pub-id pub-id-type="pmid">23145826</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Bej</surname><given-names>A. K.</given-names></name><name><surname>Dicesare</surname><given-names>J. L.</given-names></name><name><surname>Haff</surname><given-names>L.</given-names></name><name><surname>Atlas</surname><given-names>R. M.</given-names></name></person-group><year>1991</year>. <article-title>Detection of <italic>Escherichia
coli</italic> and <italic>Shigella</italic> spp. in water by using the polymerase
chain reaction and gene probes for <italic>uid</italic></article-title>.
<source><italic>Appl. Environ. Microbiol.</italic></source><volume>57</volume>:
<fpage>1013</fpage>&#x02013;<lpage>1017</lpage>. <pub-id pub-id-type="pmid">2059028</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Belloc</surname><given-names>C.</given-names></name><name><surname>Lam</surname><given-names>D. N.</given-names></name><name><surname>Pellerin</surname><given-names>J. L.</given-names></name><name><surname>Beaudeau</surname><given-names>F.</given-names></name><name><surname>Laval</surname><given-names>A.</given-names></name></person-group><year>2005</year>. <article-title>Effect of quinolone treatment on
selection and persistence of quinolone-resistant <italic>Escherichia coli</italic> in
swine fecal flora</article-title>. <source><italic>J. Appl.
Microbiol.</italic></source><volume>99</volume>: <fpage>954</fpage>&#x02013;<lpage>959</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1365-2672.2005.02667.x</pub-id><pub-id pub-id-type="pmid">16162248</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Blondeau</surname><given-names>J. M.</given-names></name></person-group><year>2009</year>. <article-title>New concepts in antimicrobial
susceptibility testing: the mutant prevention concentration and mutant selection window
approach</article-title>. <source><italic>Vet.
Dermatol.</italic></source><volume>20</volume>: <fpage>383</fpage>&#x02013;<lpage>396</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1365-3164.2009.00856.x</pub-id><pub-id pub-id-type="pmid">20178475</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Cesaro</surname><given-names>A.</given-names></name><name><surname>Bettoni</surname><given-names>R. R.</given-names></name><name><surname>Lascols</surname><given-names>C.</given-names></name><name><surname>M&#x000e9;rens</surname><given-names>A.</given-names></name><name><surname>Soussy</surname><given-names>C. J.</given-names></name><name><surname>Cambau</surname><given-names>E.</given-names></name></person-group><year>2008</year>. <article-title>Low selection of topoisomerase mutants
from strains of <italic>Escherichia coli</italic> harbouring plasmid-borne
<italic>qnr</italic> genes</article-title>. <source><italic>J. Antimicrob.
Chemother.</italic></source><volume>61</volume>:
<fpage>1007</fpage>&#x02013;<lpage>1015</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkn077</pub-id><pub-id pub-id-type="pmid">18325893</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Ciesielczuk</surname><given-names>H.</given-names></name><name><surname>Hornsey</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>V.</given-names></name><name><surname>Woodford</surname><given-names>N.</given-names></name><name><surname>Wareham</surname><given-names>D. W.</given-names></name></person-group><year>2013</year>. <article-title>Development and evalution of a multiplex
PCR for eight plasmid-mediated quinolone-resistance determinants</article-title>.
<source><italic>J. Med. Microbiol.</italic></source><volume>62</volume>:
<fpage>1823</fpage>&#x02013;<lpage>1827</lpage>. doi: <pub-id pub-id-type="doi">10.1099/jmm.0.064428-0</pub-id><pub-id pub-id-type="pmid">24000223</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="other">Clinical and Laboratory
Standards Institute. <year>2013</year>. Performance Standards for Antimicrobial Disk and
Dilution Susceptibility Tests for Bacteria Isolated From Animals. Second Informational
Supplement. CLSI document VET01-S2, Wayne. </mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="other">Clinical and Laboratory
Standards Institute. <year>2013</year>. Performance Standards for Antimicrobial Disk and
Dilution Susceptibility Tests for Bacteria Isolated From Animals. Approved Standard-Fourth
Edition. CLSI document VET01-A4, Wayne. </mixed-citation></ref><ref id="r10"><mixed-citation publication-type="other">10.Clinical and Laboratory
Standards Institute. <year>2013</year>. Performance Standards for Antimicrobial
Susceptibility Testing; Twntieth Informational Supplement. CLSI document M100-S20, Wayne.
</mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>De Graef</surname><given-names>E. M.</given-names></name><name><surname>Decostere</surname><given-names>A.</given-names></name><name><surname>Devriese</surname><given-names>L. A.</given-names></name><name><surname>Haesebrouck</surname><given-names>F.</given-names></name></person-group><year>2004</year>. <article-title>Antibiotic resistance among fecal
indicator bacteria from healthy individually owned and kennel dogs</article-title>.
<source><italic>Microb. Drug Resist.</italic></source><volume>10</volume>:
<fpage>65</fpage>&#x02013;<lpage>69</lpage>. doi: <pub-id pub-id-type="doi">10.1089/107662904323047826</pub-id><pub-id pub-id-type="pmid">15140396</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name><surname>Everett</surname><given-names>M. J.</given-names></name><name><surname>Jin</surname><given-names>Y. F.</given-names></name><name><surname>Ricci</surname><given-names>V.</given-names></name><name><surname>Piddock</surname><given-names>L. J. V.</given-names></name></person-group><year>1996</year>. <article-title>Contributions of individual mechanisms to
fluoroquinolone resistance in 36 <italic>Escherichia coli</italic> strains isolated from
humans and animals</article-title>. <source><italic>Antimicrob. Agents
Chemother.</italic></source><volume>40</volume>:
<fpage>2380</fpage>&#x02013;<lpage>2386</lpage>. <pub-id pub-id-type="pmid">8891148</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>F&#x000e0;brega</surname><given-names>A.</given-names></name><name><surname>Madurga</surname><given-names>C.</given-names></name><name><surname>Giralt</surname><given-names>E.</given-names></name><name><surname>Vila</surname><given-names>J.</given-names></name></person-group><year>2009</year>. <article-title>Mechanism of action of and resistance to
quinolones</article-title>. <source><italic>Microb.
Biotechnol.</italic></source><volume>2</volume>: <fpage>40</fpage>&#x02013;<lpage>61</lpage>.
doi: <pub-id pub-id-type="doi">10.1111/j.1751-7915.2008.00063.x</pub-id><pub-id pub-id-type="pmid">21261881</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Gebru</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>J. S.</given-names></name><name><surname>Chang</surname><given-names>Z. Q.</given-names></name><name><surname>Hwang</surname><given-names>M. H.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>S. C.</given-names></name></person-group><year>2009</year>. <article-title>Integration of pharmacokinetic and
pharmacodynamic indices of orbifoxacin in beagle dogs after a single intravenous and
intramuscular administration</article-title>. <source><italic>Antimicrob. Agents
Chemother.</italic></source><volume>53</volume>:
<fpage>3024</fpage>&#x02013;<lpage>3029</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01346-08</pub-id><pub-id pub-id-type="pmid">19398644</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>Guardabassi</surname><given-names>L.</given-names></name><name><surname>Schwarz</surname><given-names>S.</given-names></name><name><surname>Lloyd</surname><given-names>D. H.</given-names></name></person-group><year>2004</year>. <article-title>Pet animals as reservoirs of
antimicrobial-resistant bacteria</article-title>. <source><italic>J. Antimicrob.
Chemother.</italic></source><volume>54</volume>:
<fpage>321</fpage>&#x02013;<lpage>332</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkh332</pub-id><pub-id pub-id-type="pmid">15254022</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Jacoby</surname><given-names>G. A.</given-names></name><name><surname>Griffin</surname><given-names>C. M.</given-names></name><name><surname>Hooper</surname><given-names>D. C.</given-names></name></person-group><year>2011</year>. <article-title><italic>Citrobacter</italic> spp. as a
source of <italic>qnrB</italic> alleles</article-title>. <source><italic>Antimicrob.
Agents Chemother.</italic></source><volume>55</volume>:
<fpage>4979</fpage>&#x02013;<lpage>4984</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.05187-11</pub-id><pub-id pub-id-type="pmid">21844311</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Johnston</surname><given-names>K. L.</given-names></name><name><surname>Lamport</surname><given-names>A. I.</given-names></name><name><surname>Ball&#x000e8;vre</surname><given-names>O. P.</given-names></name><name><surname>Batt</surname><given-names>R. M.</given-names></name></person-group><year>2000</year>. <article-title>Effects of oral administration of
metronidazole on small intestinal bacteria and nutrients of cats</article-title>.
<source><italic>Am. J. Vet. Res.</italic></source><volume>61</volume>:
<fpage>1106</fpage>&#x02013;<lpage>1112</lpage>. doi: <pub-id pub-id-type="doi">10.2460/ajvr.2000.61.1106</pub-id><pub-id pub-id-type="pmid">10976744</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Kanamori</surname><given-names>H.</given-names></name><name><surname>Yano</surname><given-names>H.</given-names></name><name><surname>Hirakata</surname><given-names>Y.</given-names></name><name><surname>Endo</surname><given-names>S.</given-names></name><name><surname>Arai</surname><given-names>K.</given-names></name><name><surname>Ogawa</surname><given-names>M.</given-names></name><name><surname>Shimojima</surname><given-names>M.</given-names></name><name><surname>Aoyagi</surname><given-names>T.</given-names></name><name><surname>Hatta</surname><given-names>M.</given-names></name><name><surname>Yamada</surname><given-names>M.</given-names></name><name><surname>Nishimaki</surname><given-names>K.</given-names></name><name><surname>Kitagawa</surname><given-names>M.</given-names></name><name><surname>Kunishima</surname><given-names>H.</given-names></name><name><surname>Kaku</surname><given-names>M.</given-names></name></person-group><year>2011</year>. <article-title>High prevalence of extended-spectrum
&#x003b2;-lactamase and <italic>qnr</italic> determinants in <italic>Citrobacter</italic>
species from Japan: dissemination of CTX-M-2</article-title>. <source><italic>J.
Antimicrob. Chemother.</italic></source><volume>66</volume>:
<fpage>2255</fpage>&#x02013;<lpage>2262</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkr283</pub-id><pub-id pub-id-type="pmid">21733965</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Lawrence</surname><given-names>M.</given-names></name><name><surname>KuKanich</surname><given-names>K.</given-names></name><name><surname>Kukanich</surname><given-names>B.</given-names></name><name><surname>Heinrich</surname><given-names>E.</given-names></name><name><surname>Coetzee</surname><given-names>J. F.</given-names></name><name><surname>Grauer</surname><given-names>G.</given-names></name><name><surname>Narayanan</surname><given-names>S.</given-names></name></person-group><year>2013</year>. <article-title>Effect of cefovecin on the fecal flora of
healthy dogs</article-title>. <source><italic>Vet.
J.</italic></source><volume>198</volume>: <fpage>259</fpage>&#x02013;<lpage>266</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tvjl.2013.04.010</pub-id><pub-id pub-id-type="pmid">23702279</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Lloyd</surname><given-names>D. H.</given-names></name></person-group><year>2007</year>. <article-title>Reservoirs of antimicrobial resistance in
pet animals</article-title>. <source><italic>Clin. Infect.
Dis.</italic></source><volume>45</volume><issue>Suppl 2</issue>:
<fpage>S148</fpage>&#x02013;<lpage>S152</lpage>. doi: <pub-id pub-id-type="doi">10.1086/519254</pub-id><pub-id pub-id-type="pmid">17683019</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Matsumoto</surname><given-names>S.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Komatsu</surname><given-names>T.</given-names></name><name><surname>Kitadai</surname><given-names>Y.</given-names></name><name><surname>Horii</surname><given-names>Y.</given-names></name><name><surname>Katae</surname><given-names>H.</given-names></name></person-group><year>1997</year>
<article-title>Absorption, distribution and excretion of
orbifloxacin in dogs and cats</article-title>. <source><italic>Jpn. J. Vet. Med.
Assoc.</italic></source><volume>50</volume>: <fpage>470</fpage>&#x02013;<lpage>474</lpage>.
doi: <pub-id pub-id-type="doi">10.12935/jvma1951.50.470</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Miranda</surname><given-names>J. M.</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>B. I.</given-names></name><name><surname>Fente</surname><given-names>C. A.</given-names></name><name><surname>Barros-Vel&#x000e1;zquez</surname><given-names>J.</given-names></name><name><surname>Cepeda</surname><given-names>A.</given-names></name><name><surname>Franco</surname><given-names>C. M.</given-names></name></person-group><year>2008</year>. <article-title>Evolution of resistance in poultry
intestinal <italic>Escherichia coli</italic> during three commonly used antimicrobial
therapeutic treatments in poultry</article-title>. <source><italic>Poult.
Sci.</italic></source><volume>87</volume>: <fpage>1643</fpage>&#x02013;<lpage>1648</lpage>. doi:
<pub-id pub-id-type="doi">10.3382/ps.2007-00485</pub-id><pub-id pub-id-type="pmid">18648061</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name><surname>Navia</surname><given-names>M. M.</given-names></name><name><surname>Ruiz</surname><given-names>J.</given-names></name><name><surname>Ribera</surname><given-names>A.</given-names></name><name><surname>de Anta</surname><given-names>M. T.</given-names></name><name><surname>Vila</surname><given-names>J.</given-names></name></person-group><year>1999</year>. <article-title>Analysis of the mechanisms of quinolone
resistance in clinical isolates of <italic>Citrobacter frendii</italic></article-title>.
<source><italic>J. Antimicrob. Chemother.</italic></source><volume>44</volume>:
<fpage>743</fpage>&#x02013;<lpage>748</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/44.6.743</pub-id><pub-id pub-id-type="pmid">10590274</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="book"><person-group><name><surname>Papich</surname><given-names>M. G.</given-names></name><name><surname>Riviere</surname><given-names>J. E.</given-names></name></person-group><year>2009</year> Fluoroquinolone antimicrobial drugs. pp. 983&#x02013;1011.
<italic>In</italic>: Veterinary Pharmacology and Therapeutics, 9th ed. (Riviere, J. E.
and Papich, M. G. eds.), John Wiley and Sons, Ames.</mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name><surname>Piddock</surname><given-names>L. J.</given-names></name></person-group><year>1999</year>. <article-title>Mechanisms of fluoroquinolone resistance:
an update 1994&#x02013;1998</article-title>.
<source><italic>Drugs</italic></source><volume>58</volume><issue>Suppl.
2</issue>: <fpage>11</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.2165/00003495-199958002-00003</pub-id><pub-id pub-id-type="pmid">10553699</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Harada</surname><given-names>K.</given-names></name><name><surname>Kataoka</surname><given-names>Y.</given-names></name></person-group><year>2013</year>. <article-title>Mutant prevention concentration of
orbifloxacin: comparison between <italic>Escherichia coli, Pseudomonas
aeruginosa</italic>, and <italic>Staphylococcus pseudintermedius</italic> of canine
origin</article-title>. <source><italic>Acta Vet.
Scand.</italic></source><volume>55</volume>: <fpage>37</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1751-0147-55-37</pub-id><pub-id pub-id-type="pmid">23634902</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name><surname>Stalder</surname><given-names>G. L.</given-names></name><name><surname>Loncaric</surname><given-names>I.</given-names></name><name><surname>Walzer</surname><given-names>C.</given-names></name></person-group><year>2014</year>. <article-title>Diversity of enterobacteria including
&#x003b2;-lactamase producing isolates associated with the Spanish slug (<italic>Arion
vulgaris</italic>)</article-title>. <source><italic>Sci. Total
Environ.</italic></source><volume>479&#x02013;480</volume>: <fpage>11</fpage>&#x02013;<lpage>16</lpage>.
doi: <pub-id pub-id-type="doi">10.1016/j.scitotenv.2014.01.103</pub-id><pub-id pub-id-type="pmid">24534696</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name><surname>Thomson</surname><given-names>K. S.</given-names></name></person-group><year>2010</year>. <article-title>Extended-spectrum &#x003b2;-lactamases, AmpC, and
carbapenemase issues</article-title>. <source><italic>J. Clin.
Microbiol.</italic></source><volume>48</volume>:
<fpage>1019</fpage>&#x02013;<lpage>1025</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JCM.00219-10</pub-id><pub-id pub-id-type="pmid">20181902</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group><name><surname>Trott</surname><given-names>D. J.</given-names></name><name><surname>Filippich</surname><given-names>L. J.</given-names></name><name><surname>Bensink</surname><given-names>J. C.</given-names></name><name><surname>Downs</surname><given-names>M. T.</given-names></name><name><surname>McKenzie</surname><given-names>S. E.</given-names></name><name><surname>Townsend</surname><given-names>K. M.</given-names></name><name><surname>Moss</surname><given-names>S. M.</given-names></name><name><surname>Chin</surname><given-names>J. J. C.</given-names></name></person-group><year>2004</year>. <article-title>Canine model for investigating the impact
of oral enrofloxacin on commensal coliforms and colonization with multidrug-resistant
<italic>Escherichia coli</italic></article-title>. <source><italic>J. Med.
Microbiol.</italic></source><volume>53</volume>:
<fpage>439</fpage>&#x02013;<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1099/jmm.0.05473-0</pub-id><pub-id pub-id-type="pmid">15096555</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group><name><surname>van den Bogaard</surname><given-names>A. E.</given-names></name><name><surname>Stobberingh</surname><given-names>E. E.</given-names></name></person-group><year>2000</year>. <article-title>Epidemiology of resistance to
antibiotics. Links between animals and humans</article-title>. <source><italic>Int. J.
Antimicrob. Agents</italic></source><volume>14</volume>:
<fpage>327</fpage>&#x02013;<lpage>335</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0924-8579(00)00145-X</pub-id><pub-id pub-id-type="pmid">10794955</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group><name><surname>Versalovic</surname><given-names>J.</given-names></name><name><surname>Koueth</surname><given-names>T.</given-names></name><name><surname>Lupski</surname><given-names>J. R.</given-names></name></person-group><year>1991</year>. <article-title>Distribution of repetitive DNA sequences
in eubacteria and application to fingerprinting of bacterial genomes</article-title>.
<source><italic>Nucleic Acids Res.</italic></source><volume>19</volume>:
<fpage>6823</fpage>&#x02013;<lpage>6831</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/19.24.6823</pub-id><pub-id pub-id-type="pmid">1762913</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group><name><surname>Walker</surname><given-names>R. D.</given-names></name></person-group><year>2000</year>. <article-title>The use of fluoroquinolones for companion
animal antimicrobial therapy</article-title>. <source><italic>Aust. Vet.
J.</italic></source><volume>78</volume>: <fpage>84</fpage>&#x02013;<lpage>90</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1751-0813.2000.tb10528.x</pub-id><pub-id pub-id-type="pmid">10736664</pub-id></mixed-citation></ref></ref-list></back></article>